S&P 500   4,052.48 (+0.61%)
DOW   32,877.81 (+0.49%)
QQQ   314.84 (+0.68%)
GOOGL   101.25 (-0.14%)
NVDA   272.52 (+0.99%)
NIO   9.99 (+1.63%)
MU   63.92 (+0.60%)
DIS   98.24 (+1.41%)
AMC   5.07 (+1.40%)
PYPL   74.81 (+0.85%)
NFLX   336.20 (+1.26%)
S&P 500   4,052.48 (+0.61%)
DOW   32,877.81 (+0.49%)
QQQ   314.84 (+0.68%)
GOOGL   101.25 (-0.14%)
NVDA   272.52 (+0.99%)
NIO   9.99 (+1.63%)
MU   63.92 (+0.60%)
DIS   98.24 (+1.41%)
AMC   5.07 (+1.40%)
PYPL   74.81 (+0.85%)
NFLX   336.20 (+1.26%)
S&P 500   4,052.48 (+0.61%)
DOW   32,877.81 (+0.49%)
QQQ   314.84 (+0.68%)
GOOGL   101.25 (-0.14%)
NVDA   272.52 (+0.99%)
NIO   9.99 (+1.63%)
MU   63.92 (+0.60%)
DIS   98.24 (+1.41%)
AMC   5.07 (+1.40%)
PYPL   74.81 (+0.85%)
NFLX   336.20 (+1.26%)
S&P 500   4,052.48 (+0.61%)
DOW   32,877.81 (+0.49%)
QQQ   314.84 (+0.68%)
GOOGL   101.25 (-0.14%)
NVDA   272.52 (+0.99%)
NIO   9.99 (+1.63%)
MU   63.92 (+0.60%)
DIS   98.24 (+1.41%)
AMC   5.07 (+1.40%)
PYPL   74.81 (+0.85%)
NFLX   336.20 (+1.26%)
NASDAQ:QDEL

QuidelOrtho - QDEL Competitors

$87.86
+0.40 (+0.46%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$86.89
$88.48
50-Day Range
$82.98
$91.46
52-Week Range
$66.88
$120.61
Volume
234,879 shs
Average Volume
402,529 shs
Market Capitalization
$5.84 billion
P/E Ratio
7.09
Dividend Yield
N/A
Price Target
$123.83

QDEL vs. NEOG, LNTH, NTLA, MYGN, CLDX, TXG, ROIV, BLCO, OGN, and OPCH

Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Neogen (NEOG), Lantheus (LNTH), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), 10x Genomics (TXG), Roivant Sciences (ROIV), Bausch + Lomb (BLCO), Organon & Co. (OGN), and Option Care Health (OPCH). These companies are all part of the "medical" sector.

QuidelOrtho vs.

QuidelOrtho (NASDAQ:QDEL) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

QuidelOrtho received 102 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.77% of users gave QuidelOrtho an outperform vote while only 58.54% of users gave Neogen an outperform vote.

CompanyUnderperformOutperform
QuidelOrthoOutperform Votes
431
67.77%
Underperform Votes
205
32.23%
NeogenOutperform Votes
329
58.54%
Underperform Votes
233
41.46%

QuidelOrtho has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Neogen has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

QuidelOrtho currently has a consensus price target of $123.83, suggesting a potential upside of 40.94%. Neogen has a consensus price target of $20.00, suggesting a potential upside of 8.17%. Given QuidelOrtho's stronger consensus rating and higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Neogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QuidelOrtho
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.80
Neogen
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, QuidelOrtho had 2 more articles in the media than Neogen. MarketBeat recorded 7 mentions for QuidelOrtho and 5 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.88 beat Neogen's score of 0.30 indicating that QuidelOrtho is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
QuidelOrtho
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neogen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QuidelOrtho$3.27 billion1.79$548.70 million$12.407.09
Neogen$527.16 million7.58$48.31 million$0.05369.80

95.2% of QuidelOrtho shares are owned by institutional investors. Comparatively, 97.1% of Neogen shares are owned by institutional investors. 2.7% of QuidelOrtho shares are owned by insiders. Comparatively, 0.7% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

QuidelOrtho has a net margin of 16.80% compared to Neogen's net margin of -2.57%. QuidelOrtho's return on equity of 20.45% beat Neogen's return on equity.

Company Net Margins Return on Equity Return on Assets
QuidelOrtho 16.80% 20.45% 11.86%
Neogen -2.57% 5.56% 4.26%

Summary

QuidelOrtho beats Neogen on 15 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QDEL vs. The Competition

MetricQuidelOrthoDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.85B$2.08B$4.38B$5.87B
Dividend YieldN/A0.85%2.40%4.51%
P/E Ratio7.0929.1788.6811.49
Price / Sales1.79107.133,531.0356.69
Price / Cash4.8332.9126.7970.12
Price / Book1.188.594.555.04
Net Income$548.70M$24.17M$115.04M$191.52M
7 Day Performance3.16%2.14%1.60%1.63%
1 Month Performance1.06%-6.73%-6.46%-5.38%
1 Year Performance-22.11%-36.55%-14.89%-17.41%

QuidelOrtho Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEOG
Neogen
1.1078 of 5 stars
$18.49
+1.3%
$20.00
+8.2%
-42.1%$3.95B$630.72M369.801,039Options Volume
LNTH
Lantheus
2.81 of 5 stars
$79.32
-1.0%
$107.33
+35.3%
+40.0%$5.41B$935.06M233.29612Insider Selling
Short Interest ↓
NTLA
Intellia Therapeutics
2.5041 of 5 stars
$37.56
+4.3%
$87.18
+132.1%
-50.7%$3.31B$52.12M-6.08485Analyst Revision
MYGN
Myriad Genetics
1.7372 of 5 stars
$23.33
+2.3%
$26.20
+12.3%
-10.6%$1.89B$678.40M-16.782,600Insider Selling
CLDX
Celldex Therapeutics
1.5974 of 5 stars
$35.96
+3.4%
$66.67
+85.4%
+0.9%$1.70B$2.36M-15.05132Short Interest ↑
TXG
10x Genomics
1.7179 of 5 stars
$50.74
+3.8%
$52.00
+2.5%
-34.3%$5.85B$516.41M-34.521,239
ROIV
Roivant Sciences
2.2892 of 5 stars
$7.69
+4.6%
$12.50
+62.5%
+56.0%$5.83B$55.29M-4.32620
BLCO
Bausch + Lomb
2.4835 of 5 stars
$16.84
+0.3%
$21.54
+27.9%
N/A$5.89B$3.77B842.4212,900Short Interest ↓
OGN
Organon & Co.
3.5084 of 5 stars
$22.68
+2.0%
$31.20
+37.6%
-35.8%$5.77B$6.17B6.3210,000
OPCH
Option Care Health
3.0469 of 5 stars
$31.79
+0.4%
$40.50
+27.4%
+10.9%$5.76B$3.94B38.308,058Positive News
This page (NASDAQ:QDEL) was last updated on 3/30/2023 by MarketBeat.com Staff